期刊文献+

NP/TP方案治疗老年晚期非小细胞肺癌的临床研究

下载PDF
导出
摘要 目的研究国产长春瑞滨联合顺铂(NP方案)和紫杉醇联合顺铂/卡铂(TP方案)治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法回顾性分析86例老年晚期NSCLC患者,其中NP组38例和TP组48例,治疗2个化疗周期以上。结果两组有效率分别为47.4%和50.0%,中位生存期分别为13及15个月,两组差异无显著性;TP组静脉炎及周围神经病变发生率明显低于NP组,而肌肉关节酸痛较多见。结论NP和TP方案均为治疗中老年晚期NSCLC较好的方案,特别是TP方案不良反应更轻微,值得临床推广应用。
出处 《广东药学院学报》 CAS 2006年第5期569-571,共3页 Academic Journal of Guangdong College of Pharmacy
  • 相关文献

参考文献13

  • 1JEMAL A, MURRAY T, WARD E, et al. Cancer Statistics, 2005[J]. Cancer J Clin, 2005,55( 1 ) :10.
  • 2GRIDELLI C, PERRONE F, MONFARDINI S. Lung cancer in the elderly[ J]. Eur J Cancer, 1997,33:2 313.
  • 3GRIDELLI C, AAPRO M, ARDIZZONI A, et al. Treatment of advanced non - small - cell lung cancer in the elderly: results of an international expert panel [ J ]. J Clin Oneol, 2005,23(13) :3 125.
  • 4The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non- small cell lung cancer[J]. J Natl Cancer Inst, 1999, 85: 365.
  • 5GRIDELLI C, PERRONE F, GALLO C, et al, Vinorelbineis well tolerated and active in the treatment of elderly patients with advanced non small cell lung cancer. A two stage phase Ⅱ study[J]. Eur J Cancer, 1997, 33: 392.
  • 6JOHNSON E D H, ZHV J, SCHILLER J, et al. ECOG 1594 */a randomized phase Ill trial in metastatic non - small cell lung cancer (NSCLC). Outcome of PS 2 patients: an eastern cooperative oncology group trial [ J ]. Proc Am Soc Clin Oncol, 1999,18:416.
  • 7张湘茹,孙燕,孔维红,周生余,冯奉仪.去甲长春花碱加顺铂治疗晚期非小细胞肺癌42例[J].中华肿瘤杂志,1998,20(1):60-62. 被引量:527
  • 8张文兵,李永安,黄维安,朱小龙,韩华正.NP与GP方案治疗晚期非小细胞肺癌临床观察[J].河南肿瘤学杂志,2005,18(1):50-51. 被引量:3
  • 9殷先利,文晓萍.NE与NP方案治疗老年非小细胞肺癌疗效比较[J].肿瘤防治杂志,2003,10(6):642-644. 被引量:7
  • 10尹清云.去甲长春花碱联合顺铂治疗中晚期非小细胞肺癌的临床观察[J].肿瘤防治杂志,2003,10(12):1290-1291. 被引量:1

二级参考文献37

  • 1张湘茹,祝浩强,徐嘉彰,康晓明,勇威本,洪婉君,孙燕.鬼臼乙叉甙软胶囊治疗恶性肿瘤的临床验证报告[J].中华肿瘤杂志,1995,17(6):454-457. 被引量:6
  • 2潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 3孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1997.357-358.
  • 4Hainsworth JD, Greco FA. Paclitaxel administered by 1 - hour infusion[J]. Cancer, 1994, 74(7) : 1377.
  • 5Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2) :92.
  • 6Gandara DR, Edelman MJ, Lara P, et al. Current status and novel therapeutic approaches in advanced non-small-cell lung cancer[M]. ASCO Educational Book, 1999,35:362.
  • 7Milross CC-, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel[J ]. J Natl Cancer Inst, 1996, 88(18) : 1308.
  • 8Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase Ⅱ toxicity, response, and survival analysis[J]. J Clin Oncol, 1995, 13(8): 1860.
  • 9Rmell R,Tonuto M,Sandler A,et al.The activity of oemcitabine plus cisplatin in randomized trials in untreated patients with advanced nonsmall-cell lung cancer[J] .J Semin Oncol , 1998,25(4):27-34.
  • 10Paul A, Bunn J.Triplet chemotherapy with gemcitabine , a platinum and third agent in the treament of advanced non-small-cell lung cancer[ J]. J Semin Oncol, 1999,26( 1 ) :25-30.

共引文献539

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部